Letter: Antiviral Prophylaxis Mitigates HBV Reactivation Risk During Cancer Immunotherapy: Unresolved Challenges and Future Directions—Authors' Reply

Documenti analoghi

• Editorial: Immune Checkpoint Inhibitors and HBV Reactivation in Liver Cancer—Reassurance With Vigilance. Authors' Reply
  di: Terry Cheuk‐Fung Yip, et al.
  Pubblicazione: (2025)
• Editorial: Diabetes Management in Cirrhosis—The Window of Opportunity Before Decompensation. Authors' Reply
  di: Mary Yue Wang, et al.
  Pubblicazione: (2026)
• Editorial: Polypharmacy in MASLD—An Overlooked Epidemic Disproportionately Affecting Women and Patients With Cirrhosis
  di: Mary Yue Wang, et al.
  Pubblicazione: (2025)
• Letter: Optimising Prevention of Adverse Events and Antiviral Prophylaxis for HBV ‐Infected HCC Patients Undergoing Immunotherapy
  di: Jialing Wang, et al.
  Pubblicazione: (2025)
• Editorial: Trajectory of soluble programmed cell death protein‐1 and ligand‐1 in HBV‐infected individuals treated with pegylated interferon—Implications for stopping rules and the HBV cure programme. Authors' reply
  di: Chan Xie
  Pubblicazione: (2024)